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ABSTRACT
For 60-plus years the explanatory model for Major Depressive Disorder (MDD) has been
the monoamine theory, which states that low levels of monoamine neurotransmitters or
alterations in their post-synaptic receptors are responsible for depressive symptoms. Drugs
designed to elevate synaptic monoamine levels have remained the first line of pharmacotherapy
prescribed by clinicians for MDD patients. However, these drugs have shortcomings. Despite
evidence that current antidepressants elevate synaptic monoamine levels within hours of
administration, these drugs require four to six weeks of daily administration before symptom
relief appears. Furthermore, approximately half of patients taking typical antidepressants never
achieve full symptom relief. The therapeutic lag time and low response rates associated with
typical antidepressants suggests that elevation of monoaminergic activity may not be their true
mechanism of antidepressant action and brings into question the validity of the monoamine
theory. As a result, novel biological targets have been investigated for development of more
reliable and faster-acting antidepressants. Recent work has shown that low doses of ketamine, a
glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist, can provide depressive
symptom relief within hours of administration. What is interesting about these findings is that
ketamine works on a completely different biological system than typical antidepressants.
Moreover, a number of non-drug treatments, such as electro-convulsive therapy,
psychotherapies, and exercise have proven efficacious in treating depressive symptoms.
Understanding the biological mechanisms that underlie all of these various treatment modalities
may provide evidence for a more valid explanatory model of MDD. In a review of relevant
ii

literature examining biologic alterations produced by monoaminergic antidepressants, ketamine
and other glutamatergic agents, psychotherapies, electroconvulsive shock therapy, or exercise a
commonality was identified: all of the treatments promote the growth of new synapses
(synaptogenesis) and the growth of new neurons (neurogenesis). This finding prompts support
for the developing Stress-Neurogenic Theory of depression. This theory suggests depressive
symptoms are due to chronic, unpredictable stressors which stimulate the production of stress
hormones leading to cell death in major brain areas and treatment for depression is dependent
upon stimulating the brain’s natural processes responsible for the growth of new connections and
new cells in affected brain regions.
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1.0 INTRODUCTION

According to the National Institute of Mental Health, major depressive disorder (MDD),
or major depression, is characterized by a combination of symptoms that interfere with a
person’s ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Some people
may experience only a single depressive episode within their lifetime, but more often a person
will experience multiple depressive episodes. According to the DSM-5, five of the following
criteria must be met in the same two week period to diagnose someone as suffering from a major
depressive episode: 1) depressed mood most of the day, nearly all day; 2) diminished interest or
pleasure in all, or almost all activities most of the day nearly every day; 3) significant weight
loss when not dieting or significant weight gain, or a decrease or increase in appetite nearly
every day; 4) insomnia or hypersomnia nearly every day; 5) psychomotor retardation or
agitation nearly every day; 6. Fatigue or loss of energy nearly every day; 7) feelings of
worthlessness or excessive or inappropriate guilt nearly every day; 8) diminished ability to think
or concentrate, or indecisiveness, nearly every day; 9) recurrent thoughts of death other than fear
of death, recurrent suicidal ideation, or a suicide attempt, or a specific plan for committing
suicide (Diagnostic and Statistics Manual-5).
A 2003 study using 9090 participants found that 16.2% suffered from an MDD episode
during their lifetime and that 6.6% of the participants experienced a major depressive episode
1

during the 12 months before the study. If those sample numbers were extrapolated to the
general population, the study suggests that between 33-35 million U.S. adults experience a major
depressive episode in their lifetime and between 13-14 million U.S. adults experience at least one
depressive episode during a 12-month period (Kessler et al, 2003). In a 2005 follow up study
designed to estimate 12- month prevalence, severity, and comorbidity of DSM-IV anxiety, mood,
impulse control, and substance abuse disorders found that 6.7% of the subjects experienced a
major depressive episode in the preceding 12 months, findings consistent with the 2003 study
(Kessler et al., 2005). The estimated economic cost of MDD in 2000, which includes the cost of
treatment and loss of work productivity, was estimated at $83.1 billion in the United States alone
(Greenberg et al. 2003).
While the economic impact of MDD is staggering, major depressive disorder is not the
only type of depressive disorder. Other common depressive subtypes are treatment-resistant
depression, bipolar depression, and dysthymic disorder. Although it is not recognized by the
Diagnostic Statistical Manual (DSM) used by clinicians for diagnosis of mental disorders,
treatment- resistant depression, or TRD, is relatively common in MDD cases as only 50% of
MDD patients respond to typical pharmacotherapies for depression (Papakostas, G. I., & Fava,
M. 2010). Currently the FDA defines treatment-resistant depression as the failure of depressed
patients to respond to adequate dosing and regimen of pharmacotherapies from two distinct
classes of traditional antidepressants. This diagnostic criteria can only be made post-treatment
thus leaving patients to continue to suffer from depressive symptoms. A 2010 study by Fostick
and colleagues revealed that patients diagnosed with TRD suffer from more severe MDD
symptoms as scored on the Hamilton Depression Rating Scale (HDRS). In this study 107
2

patients diagnosed with MDD were interviewed by a psychiatrist who was blind to the purpose
of the study and to the treatment history of the patients and scored the severity of depressive
symptoms using the HDRS. The study reported that non-TRD patients had a mean score of 9.8
versus a mean score of 18.6 for TRD patients (Fostick et al., 2010). This same study also found
a positive correlation between depression severity and economic impact. Patients with more
severe depression had increased direct costs, such as blood and imaging tests, physician visits,
and hospitalization costs, as well as increased indirect costs, such as lower worker productivity
and higher worker absenteeism. In a recent meta-analysis of the cost of MDD patient care from
2001 to 2009, it was found that the medical expenses for TRD patients was almost 30% higher
than normal MDD patients (Olchanski et al., 2013). The association of increased expenses and
TRD was confirmed in an analysis by Gibson and colleagues who found that, on average,
depressed patients deemed treatment resistant had 40% higher medical costs compared to
respondent MDD patients (Gibson T. et al., 2010).
While the economic impact of depressive disorders is significant, not only to the sufferer
but to the general public as well, the more troubling symptom of these depressive disorders is
suicide ideations and attempts. According to the Center for Disease Control (CDC) website,
suicide is defined as “death caused by self-directed injurious behavior with intent to die as a
result of the behavior.” (see www.cdc.gov). The CDC also lists suicide as the tenth leading cause
of death in 2015 and the third leading cause of death among people between the ages of 10 and
14 and the second leading cause of death among people between the ages of 15 and 34 in that
same year. Furthermore, the CDC reports that there were 44,193 suicides in 2015 compared to
17,793 homicides.
3

The economic and personal impact of depressive disorders make the need for effective
therapies for MDD paramount. Identifying and developing more effective and faster acting
antidepressants requires our full understanding of the etiopathology associated with the disorder.
The purpose of this paper is to review the development of the monoamine theory of depression,
examine the validity of the findings that prompted it, and identify any common mechanisms
shared by all forms of efficacious treatment for depression. If any commonality in biological
alterations exists between the various treatment modalities, it may prove useful in developing a
more valid explanatory model for MDD, which would promote a new avenue in development of
more effective and faster acting antidepressant pharmacotherapies.

4

2.0 BACKGROUND

2.1: Development of the Monoamine Theory of MDD

For the past 60-plus years, the etiology of MDD has been explained through the
monoamine theory which proposes that MDD is caused by deficiencies in the monoaminergic
neurotransmitters, specifically serotonin (5-HT) and norepinephrine (NE), or by some
dysregulation of their post-synaptic receptors. Evidence in support of this theory originates from
two discoveries that occurred in the 1950’s: 1) the ability of drugs that elevate monoaminergic
activity to improve mood and 2) drugs that deplete synaptic monoamine levels induce
depression.
Prior to the 1950’s, the use of electro-convulsive shock therapy (ECT) developed by Ugo
Cerletti was the most successful treatment option for depressive disorders, but due to the
invasiveness of the procedure, it was only used as a last resort after traditional therapist-client
psychiatric methods failed. The development of the first pharmacotherapies for depression in the
1950’s occurred by chance. In 1951, pre-clinical researchers began investigating the antituberculosis properties of a class of compounds called hydrazines. After testing in animals
proved successful, clinical trials with the most promising hydrazine, isoniazid, took place in
hospitals across the state of New York. The antitubercular effects on isoniazid in these hospitals
offered hope for patients, doctors, and researchers and opened an avenue for the development of
5

structurally similar drugs, such as iproniazid which was much more effective in humans than
isoniazid. As a side note of interest, introduction of these drugs to treat tuberculosis caused the
death rate in the United States to fall from 188 deaths per 100,000 persons in 1904 to just 4 in
1952. In that same year, doctors using iproniazid to treat tuberculosis patients at Sea View
Hospital on Staten Island in New York noticed that tubercular patients treated with iproniazid
showed increased vitality and an increase in their social interactions with other patients and staff
and even led to some patients engaging in dancing in the hospital, the event immortalized in the
picture “The Patient’s Dance.” (see image below).

Image 1: Tubercular patients at Sea View Hospital dancing after treatment with hydrazines.

However, these behavioral changes were seen as side effects assumingly produced by
iproniazid’s stimulatory effects to the central nervous system and were not initially recognized
6

by the doctors as alterations to patients’ mood. In an effort to determine exactly how these
hydrazines worked biologically, in 1952 a team at Northwestern Medical School in Chicago
discovered that iproniazid was more effective than isoniazid at inhibiting monoamine oxidase
(MAO), the enzyme responsible for enzymatic degradation of the monoamine neurotransmitters
dopamine, norepinephrine, and serotonin. As a result of inhibiting this enzyme, iproniazid
increases the amount of the monoamine neurotransmitters in the synaptic cleft and thus increases
the activation of their post-synaptic receptors. In 1957, researchers at the National Institute of
Health (NIH) led by Sydney Udenfriend observed that administration of iproniazid, but not
isoniazid, in animals resulted in rapid elevation in brain levels of the monoamine
neurotransmitter serotonin, an important discovery in iproniazid’s effect on the central nervous
system. These findings led to iproniazid being the favored choice in trials for anti-tubercular
properties.
However, iproniazid was eventually abandoned as a treatment option for tuberculosis due
to a poor safety profile, except in extreme cases, though some researchers concluded that the
stimulatory side effects of iproniazid could be a primary effect if used as treatment for certain
psychiatric disorders. Researchers and practitioners in the United States began to use and report
the mood altering effects of the hydrazine compounds isoniazid and iproniazid. In 1952, Jean
Delay reported that two out of four patients (50%) treated with isoniazid showed depressive
symptom improvements (Delay, Lainé, & Buisson, 1952). In 1953 a two to three week trial with
iproniazid in 11 psychiatric patients suffering from various disorders reported that two of the 11
(18%) “appeared improved” in opinion of themselves, interest in general activity in the ward,
and general appearance (Smith, 1953). And also in 1953, Salzer and Lurie used isoniazid to treat
7

a group of 40 depressed patients and reported that approximately 70% showed improvement in
mood (Salzer and Laurie, 1953). In the publication of findings from this last study, the
psychiatrist Max Lurie, a private practice psychiatrist in Cincinnati, along with Harry Salzer first
used the term “antidepressant” to describe the mood enhancing effects of the hydrazine isoniazid
in depressed patients.
Together, the discovery of the hydrazine’s effect on mood and their biological
mechanism of action (inhibition of monoamine oxidase resulting in increased synaptic activity of
the three monoamines) was an important step in developing a biological explanation for
depression. The second piece of evidence in the development of the monoamine model of
depression came from reserpine’s ability to induce depressive states. Reserpine is the primary
active compound from the Indian snakeroot plant (rauwolfia serpentine) and is capable of
blocking the storage of monoamines into vesicles in the pre-synaptic terminal. By blocking the
vesicular monoaminergic transporter (VMAT), reserpine reduces the amount of monoamine
neurotransmitters stored in presynaptic vesicles. While normal exocytosis processes remain
uninterrupted, the vesicle is empty and releases very little, if any, monoamines into the synapse,
thus reducing activity at their post-synaptic receptors. The behavioral and physiological effects
of reserpine had long been known to the people of India. It was commonly used to treat snake
bites, provide a calming effect to infants and mental patients, and was later determined to lower
blood pressure and was marketed as an antihypertensive drug in India in the 1930’s. Reports
from India on the use of Rauwolfia and/or its primary compound reserpine in calming patients
with mental disorders prompted its trial in treating schizophrenic patients at Rockland State
Hospital in New York in 1954. While it failed to provide psychotic symptom relief, it was noted
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to produce behavioral sedation as measured by a reduction in both assaults and the need for
patient restraint (Kline, N., 1954). However, reserpine still proved useful in treating hypertension
and a number of early trials in patients suffering from psychiatric illnesses and/or hypertension
reported reserpine’s depressionogenic effects (Fries E., 1954; Harris T., 1957).
Together, the two discoveries 1) that early anti-tubercular drugs improved mood and
elevated synaptic monoamine levels and 2) that reserpine reduces synaptic monoamine levels
and is depressionogenic, led to the development of the Monoamine Theory of Depression.
Today there are a number of different classes of drugs that increase synaptic
monoaminergic activity through various mechanisms. As described above, early antidepressants
attempted to increase synaptic monoamine levels by inhibiting their enzymatic degradation via
monoamine oxidase (i.e. monoamine oxidase inhibitors or MAOI’s), thus prolonging
monoamine availability in the synapse and increase activity on their post-synaptic receptors.
However, MAOI’s proved to have potentially deadly dietary interactions and have fallen out of
use. More recent drugs utilized to treat MDD comprise three separate classes of drugs, each with
its own mechanism of action of increasing synaptic levels of serotonin and/or norepinephrine and
include 1) tricyclic inhibitors (TCA’s) of both NE and 5-HT reuptake transporters, such as
imipramine, 2) selective serotonin reuptake inhibitors (SSRI's), such as fluoxetine, and 3) newer
selective NE reuptake inhibitors (SNRI's), such as maprotiline. However, the Monoamine
Theory of MDD and the drugs designed to treat depression based on that theory are not without
their issues.
Firstly, the monoamine theory of depression was “accidentally” discovered. The mood
enhancing effects of the hydrazine antidepressants were initially mistaken for simple stimulatory
9

effects on the nervous system. Through some sharp clinical observation, some researchers
proposed that these side effects could be considered primary effects in a different population of
patients. However, the early clinical trials with hydrazines reported only modest
“antidepressant” effects in patients with response rates varying between 18 to 70% (cited above).
These findings were a major underpinning of the monoamine theory, however, they are not
without their criticisms. In evaluating these studies, we should consider the criteria the
researchers were using for their diagnosis of depression. The major diagnostic tool during the
time these studies took place was the DSM-I, published in 1951 and prior to its publishing, there
were a number of different references offering differing diagnostic criteria for depression. In the
DSM-I, affective disorders such as depression were grouped under the larger category of
“Psychoneurotic Reactions,” with the cause of such disorders attributed to two factors: 1)
“psychogenic” factors such as those proposed under the Freudian theories of unresolved
unconscious conflicts, and 2) some undefinable and intangible structural change (i.e. unknown
biological alterations). The DSM-I does not actually list any direct symptoms of depression, or
Depressive Reactions, but instead gives a general description of overall depressive behavior
attributing it to recent losses in the patient’s life and/or some sense of guilt being experienced by
the patient. The limited description of depressive symptoms given in the first edition of the DSM
brings into question the validity of diagnoses made in early patients, and thus early clinical trials.
It also brings into question the validity of how “antidepressant” effects were measured in patients
in these early trials. For example, the clinical study performed by Smith in 1953 proposed that
improvements or increases in self-opinion, curiosity of hospital activities, and personal hygiene
as evidence for iproniazid’s antidepressant effects. While changes in these behaviors were
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certainly an improvement for patients, are they truly representative of a positive change in
mood?
Another issue with these findings lies in the research methodology employed in these
early clinical studies. None of them report using any kind of control group for comparison, nor
report any blind procedures but instead measure improvement via researcher observations. Lack
of control in these studies suggest the possibility of a placebo effect in patients not blinded to
experimental design and the possibility of researcher bias in the interpretation of behavioral
changes/improvement in non-blinded observers, both of which are a huge concern in
antidepressant trials. In an analysis of clinical trials with monoaminergic antidepressants in the
years between 1985 and 1997, Khan and Brown found that investigator and rater bias influenced
the magnitude of symptom reduction in these studies, reporting the following on the difference
between monoaminergic antidepressants and placebo:
“Specifically, it became evident that the magnitude of symptom reduction was about 40%
with antidepressants and about 30% with placebo.” (Khan and Brown, 2015).
Additionally, the authors found that evaluators of depression symptoms graded a higher
magnitude of effect for antidepressants in non-blind trials compared to antidepressant effects in
blinded trials. While the analysis by Khan and Brown did not directly analyze the early clinical
trials with hydrazines, the lack of proper controls in those early trials suggest their results may
have also been influenced by observer/researcher biases and/or the placebo effect. These factors
cast doubt on one of the pillars that served as the basis of the monoamine theory.
The other pillar in the development of the monoamine theory of MDD was the
depressionogenic effects of reserpine. As detailed above, reserpine’s mechanism results in a
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depressed mood state by reducing synaptic monoamine levels. However, the early studies
demonstrating reserpine’s effect on mood were also flawed. The trials conducted by Freis in
1952 and Harris in 1957 included patients suffering from chronic illnesses and/or hypertension.
Depression rates among the chronically ill are very high (approximately 50% according to Bant,
1978). Depression thought to be caused by reserpine in chronically ill patients could be
misattributed to the drug instead of being attributed no normal rates of depression within that
specific population. Furthermore, the depression rates for hypertension patients that were taking
reserpine was reported at approximately 10% (Baumeister et al., 2003). If you recall from the
introduction in this paper, a 2003 study by Kessler et al. found that approximately 6.6% of the
general population suffered from a depressive episode within the prior 12 months leading up to
the study. Comparison of these statistics imply only a marginal increase in depression rates
among hypertension patients taking reserpine. Combined, these issues suggest that reserpine may
not actually be depressionogenic.
Finally, current antidepressants developed based on the monoamine theory have some
serious limitations. These drugs, as a whole, possess numerous undesirable side effects
including dizziness, constipation, hypertension and other cardiac issues, and sexual dysfunctions.
While it has been demonstrated that monoaminergic antidepressants are capable of elevating
synaptic monoamine levels within hours after administration, four to six weeks of daily drug
administration is needed to produce adequate MDD symptom relief (Paul & Skolnick, 2003;
Trivedi, Rush, Wisniewski, 2006). Moreover, not all MDD patients show depressive symptom
alleviation following monoaminergic antidepressant use. It is reported that between 40 to 60%
of MDD patients fail to see depressive symptom relief following adequate regimens of typical
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antidepressants (Paul, Skolnick, 2003; Trivedi, Rush, Wisniewski, 2006) resulting in roughly
half of all MDD patients undergoing treatment with typical antidepressants being diagnosed with
TRD.
The moderate response rate and lag time of therapeutic effects from drugs targeting
monoaminergic systems suggests that increased synaptic monoaminergic levels are not sufficient
for depressive symptom relief and brings into question the validity of the monoamine theory of
depression. If these drugs elevate synaptic monoamine levels within hours, why does it take
weeks before depressive symptom relief appears? And if the Monoamine Theory of depression is
a valid explanatory model, why do only half of people who take current antidepressants show
symptom relief/remission? These treatment shortcomings suggest that the true therapeutic
mechanism of current antidepressants may be some other downstream process or processes that
are eventually achieved as a result of the increases in monoamine activity produced by
antidepressants, and not their direct and immediate influence on monoaminergic neurotransmitter
levels. In a review of the mechanisms of antidepressants and their effects, while commenting on
the mechanism of tricyclic antidepressants, Andrade and Rao explained it in these terms:
“A fundamental problem with the synaptic explanations described above is that, while
they are immediate, the antidepressant response is delayed. For example, the TCA’s inhibit the
reuptake of monoamines as soon as they are absorbed into the body and transported across the
blood-brain-barrier, i.e. within hours of administration. However, the antidepressant response
takes weeks or longer to develop and complete and, hence, for response and remission to occur.
Therefore to say that the TCA’s act by increasing the presence of neurotransmitters in the
synapse is about as complete as saying that cars run because of an increased presence of fuel in
13

the tank. Clearly, just as mechanisms downstream to the presence of fuel in the tank enable a car
to move, so too must there be something downstream to increase the synaptic availability of
monoamines to fully explain antidepressant mechanisms.” (Andrade and Kumar Rao, 2010).
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2.2: Secondary Effects of Monoaminergic Antidepressants

Numerous preclinical studies report that many of the conventional monoaminergic
antidepressants have a number of secondary biological effects. For example, typical
antidepressants increase neurotrophic growth factors, such as brain-derived neurotropic factor
(BDNF) (reviewed in Altar, 1999). These growth factors are responsible for neuronal survival,
synaptogenesis, and neurogenesis. Chronic administration of representative compounds from
monoaminergic antidepressant classes have been shown to increase the required genetic
precursor, messenger ribonucleic acid (mRNA), which codes for BDNF production (Nibuya,
Morinobu, Duman, 1995; Fujimaki et al., 2000 de Foubert, et al., 2004; Reagan, et al., 2007).
Additionally, in the study cited above by Reagan and colleagues, the researchers measured
increases in BDNF protein levels themselves in several major brain regions implicated in the
pathology of MDD following chronic administration of monoaminergic antidepressants.
Interestingly, de Foubert and colleagues reported that chronic administration (21 days) but not
acute administration of the SSRI fluoxetine (Prozac) was required to produce an increase in
BDNF mRNA levels, a time course similar to the requirements for the antidepressant effects of
fluoxetine and other monoaminergic-based drugs seen in MDD sufferers (4 – 6 weeks).
Furthermore, pre-clinical trials utilizing rodent models of depression have shown that direct
administration of BDNF can alleviate depression-like behavior in these models within minutes
following administration (Siuciak, et al., 1997).
In addition to conventional antidepressants effect on BDNF, monoaminergic
antidepressants have also been shown to modulate the expression of specific glutamate receptors.
15

Two studies by Barbon and colleagues examine the effects of conventional antidepressants on
glutamatergic 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propionic acid (AMPA) receptor
expression. In 2006, Barbon and colleagues found that after 14 days of treatment with either the
SSRI fluoxetine or the SNRI reboxetine, rat hippocampal and prefrontal cortex (PFC) samples
showed increases in AMPA receptor mRNA (Barbon et al., 2006). In a 2011 follow-up time
course study, Barbon and colleagues examined the effect of chronic administration of classic
antidepressants on the number of expressed AMPA receptors. However, in this study rodent
hippocampal and PFC samples were collected at multiple time points over a two week period
from animals treated with either fluoxetine or reboxetine and were analyzed for AMPA receptor
mRNA. The researchers found non-significant increases in AMPA receptor mRNA was achieved
after one week of treatment and significant, and maximal, AMPA receptor mRNA upregulation
was achieved after 14 days of treatment (Barbon et al., 2011). This finding is incredibly
important as the time-course for depressive symptom relief under chronic (daily) administration
of typical antidepressants is four to six weeks. The studies by Barbon et al., demonstrate that
chronic administration of typical antidepressants increases the number of receptors of a
completely different neurotransmitter system, the glutamate system, and implicate the glutamate
system as a possible mediator of their antidepressant effects.
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2.3: The Role of Glutamate in MDD

Glutamate is the major excitatory neurotransmitter in the nervous system and it plays a
major role in learning and memory, neurogenesis, synaptogenesis, and neuronal survival
(Matteson, 2008). Glutamatergic neurons are located throughout the brain with high
concentrations found in the cerebral cortex, amygdala, hippocampus, and cerebellum, among
others, which project to numerous subcortical structures such as the striatum, thalamus, some
limbic system structures, and areas in the brainstem. There are two distinct classes of glutamate
receptors, ionotropic and metabotropic, and each class has multiple receptor subtypes. The
ionotropic family consists of kainate, N-methyl D-aspartate (NMDA), and 2-amino-3-(5-methyl3-oxo-1,2- oxazol-4-yl) propanoic acid (AMPA) receptors. There are 8 metabotropic glutamate
receptors (mGluRs; labeled 1 through 8) that are sub-divided into 3 individual families based on
functionality and location.
There is a growing body of evidence implicating that the glutamatergic system plays a
role in the neurobiology of MDD. Several studies have reported increased glutamate levels in
blood and cerebrospinal fluid (CSF) of patients suffering from MDD (Kim, 1982; Altamura et
al., 1993; Mauri, 1998; Mitani et al., 2006). Mitani and colleagues also reported a positive
correlation between plasma glutamate levels and the severity of symptoms in patients with MDD
(Mitani et al., 2006). Furthermore, increased levels of glutamate have been reported in the
frontal cortex of postmortem brain samples from MDD patients (Hashimoto, Sawa, Iyo, 2007b),
and an in vivo study using magnetic resonance spectroscopy (MRS) revealed elevated levels of
glutamate in the occipital cortex of MDD patients (Sancora et al., 2004a). However, numerous
17

studies using MRS have reported contrasting findings of decreased levels of glutamate and its
precursor glutamine in the anterior cingulate cortex, prefrontal cortex, and hippocampus of MDD
patients (Auer et al., 2000; Ajilore et al., 2007; Hasler et al., 2007; Block et al., 2009).
Postmortem studies of brain samples from MDD patients show decreased levels of glutamate
NMDA receptor subtypes, AMPA receptor subtypes, and one metabotropic glutamate receptor
(mGluR5) in various brain regions such as the superior temporal cortex, perirhinal cortex,
hippocampus, and prefrontal cortex (Nudmam-Thanoi, 2004; Beneyto et al., 2007; Law, Deakin,
2001; Feyissa et al., 2009). When combined, these findings suggest that alterations in glutamate
levels play a role in the pathophysiology of MDD.
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2.4: Glutamate and Neurogenic Processes

In 1966, Terje Lomo discovered that repeated high frequency stimulation of
glutamatergic neurons via microelectrodes in the hippocampal perforant path lead to prolonged
excitation of cells in the dentate gyrus (Lomo, 1966). Follow-up experiments demonstrated that
stimulation of the perforant path led to a state of increased excitability of cells in the dentate
gyrus lasting for up to 10 hours post stimulation (Bliss and Lomo, 1973). This long lasting
excitability was termed long-term potentiation, or LTP. Further investigations demonstrated that
LTP consists of two stages: an early and a late stage, and that NMDA receptor activation is
required for the development of both types of LTP (Collingridge et al., 1983; Harris et al., 1984).
Early LTP encompasses local changes occurring within a pre-existing synapse while late LTP
involves the stimulation of intracellular pathways that promote the growth of new synapses
(synaptogenesis) and completely new neurons (neurogenesis). Electrical stimulation of neurons
in the perforant path causes them to release glutamate into their synaptic connections with cells
in the dentate gyrus. Synaptic glutamate acts upon both AMPA and NMDA receptors on the
post-synaptic cell and co-activation of these receptors results in an excitatory post-synaptic
potential (EPSP) which triggers the production and expression of even more AMPA receptors. In
1999, Shi and colleagues demonstrated that this increase in the number of AMPA receptors
expressed into the synaptic space strengthens the synaptic connection between the pre-synaptic
and post-synaptic cells. More importantly, Shi and colleagues demonstrated that NMDA receptor
activation is a pre-requirement for increased AMPA receptor activation in that administration of
the NMDA receptor antagonist (D,L)-2-amino-5-phosphono valeric acid (AP-5) prior to
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neuronal stimulation prevented the increased expression of AMPA receptors (Shi et al., 1999).
This strengthening of the local synapse through AMPA receptor up-regulation via NMDA
receptor activation is the mechanistic process of early LTP. While early LTP is confined to the
local production of new AMPA receptors, late LTP involves activation of internal protein
pathways which stimulate the synthesis of new proteins called growth factors, such as BDNF.
Once released into the synapse, these growth factors trigger the production of new dendritic
spines on post-synaptic cells and new axon terminals on pre-synaptic cells (Nägerl et al., 2007).
Frey and colleagues demonstrated that administration of drugs that prevent the synthesis of these
growth factors prevent the induction of late LTP (Frey et al., 1988).
In his Croonian Lecture, Santiago Ramon y Cajal suggested that memories may be
formed by the strengthening of communication between already connected neurons (Cajal,
1894). If the processes of glutamatergic NMDA receptor activation and additional AMPA
receptor expression seen in LTP are the underlying biological mechanisms of learning and
memory, then it would follow that antagonism of one of these receptors should impair and/or
prevent these processes. As NMDA receptor activation is the initial step in LTP, then it makes
the most logical target to test this theory. In 1986, Morris and colleagues administered the
NMDA antagonist AP-5 to rodents exposed to spatial memory task (the Morris Water Maze,
Morris, 1984) and found that the pharmacological blockade of NMDA receptors impaired
performance, as measured by increased time of performance, compared to control animals
(Morris et al., 1986). Since the study published by Morris, there have been numerous subsequent
studies demonstrating that NMDA receptor blockade impairs learning in a variety of memory
tasks (Danysz et al., 1988; Butelman E., 1989). Furthermore, mice with increased NMDA
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receptor expression via genetic manipulation have demonstrated increased capacity for learning
and memory (Tang et al., 1999) highlighting this receptor’s role in these processes.

21

2.5: Research into Glutamate, Neurogenesis, and Depression

Early animal models of depression centered on producing a depressive phenotype
utilizing rodents. That is, producing a behavioral pattern analogous to depressive symptoms seen
in humans. Paradigms such as the forced-swim test (FST) (Porsolt, 1977), the tail-suspension
test (TST) (Steru et al., 1985), and inescapable shock paradigm (Seligman & Beagley, 1975)
became the standard pre-clinical depression models used to evaluate novel antidepressants. The
common manipulation in these models involves exposing the animal to an inescapable stressor
resulting in a reduction in behavioral activity, which is referred to as a state of learned
helplessness or behavioral despair. In these preclinical rodent models, compounds that are able
to reduce immobility (i.e. attenuate behavioral despair) are deemed to have antidepressant
effects.
As early depression models attempted to create a state of learned helplessness and given
the role of glutamatergic NMDA receptors in learning, it would follow that antagonism of this
receptor may prevent the onset of learned helplessness. Following this hypothesis, Trullas and
Skolnick evaluated two NMDA receptor antagonists, AP-7 (2-amino-7-phosphonoheptanoic
acid) and MK-801 (Dizocilpine) in the FST. Both compounds were found to attenuate the
depressive phenotypes (i.e. reduce immobility) in this model equal to the effects of the tricyclic
antidepressant imipramine (Trullas and Skolnick, 1990). Since this initial investigation there
have been numerous studies replicating these results and evaluating the efficacy of other NMDA
antagonists in preclinical rodent models of depression. Two subsequent studies investigating
MK-801 demonstrated antidepressant effects in in a chronic mild stress (CMS) paradigm (Papp
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and Moryl, 1994) and again in the FST (Maj et al., 1992). However, MK-801’s antidepressant
effects have not been evaluated in clinical trials due to its numerous undesirable side effects such
as cognitive disruptions, psychotic-spectrum disorders, and the induction of brain lesions,
referred to as Olney’s lesions. Another NMDA antagonist, memantine, has also demonstrated
antidepressant effects in rodent models of depression (Reus et al., 2010, Quan et al., 2011).
However, other research has produced opposing findings with memantine in that it failed to
produce antidepressant effects in the rodent FST and the newer novelty-suppressed feeding
paradigm (Gideons et al., 2014). In line with these latter findings, clinical trials with memantine
failed to demonstrate any antidepressant effects in both unipolar (Zarate et al., 2006b) and
bipolar depressive patients (Anand et al., 2012).
More recent research has identified another NMDA antagonist, ketamine, as a potential
novel and fast acting antidepressant. Ketamine is a synthetic compound, high doses of which
have long been known to produce dissociative effects and anesthesia. As such, ketamine has
been used as a general pre-surgery anesthetic (Domino, E., Chodoff, P., Corssen, G., 1965,
Corssen, G., Miyasaka, M., Domino E., 1968). Pre-clinical animal models of depression have
demonstrated ketamine’s antidepressant effects (Sufka et al, 2009; Chaturvedi, Chandra, Bapna,
1999; Yilmaz et al., 2002). In addition to its success in animal models, ketamine has also
demonstrated antidepressant effects in clinical trials with MDD sufferers (Berman et al., 2000).
Furthermore, in a 2006 study in TRD patients, a single sub-anesthetic dose of ketamine
demonstrated antidepressant effects as early as 2 hours after administration. The same study
found that after 24 hours, 71% of the patients reported depressive symptom improvement, and
these antidepressant effects of this one time administration were sustained for more than a week
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(Zarate, 2006a). This finding of ketamine’s antidepressant effects in TRD sufferers specifically
has been replicated in another, more recent, clinical trial (Price et al., 2009). However, despite
these promising findings, ketamine is structurally similar to phencyclidine (PCP) and produces a
similar dissociative state, hallucinations, and euphoria, and possess abuse/addictive potential
(Siegel, 1978), making it an unlikely candidate for long-term use in the clinical treatment of
depressive disorders. Additionally, given the NMDA receptor’s role in learning and memory, an
investigation into the cognitive effects of ketamine administration in TRD patients found that
after an intravenous infusion of 0.5 mg/kg dose of ketamine, patients showed cognitive
impairments as measured by scores on a battery of cognitive tests including intelligence quotient
(IQ) tests and the MATRICS Consensus Cognitive Battery test (Murrough et al., 2013). Yet, the
preclinical and clinical findings with ketamine are promising and prompted research on other
glutamatergic targets.
The two glutamatergic receptors NMDA and AMPA are co-localized on the postsynaptic dendritic spine and, as such, co-activate upon the release and binding of the
neurotransmitter glutamate. Therefore, probing the nearby AMPA receptor for antidepressant
effects was the first and most obvious glutamatergic candidate. A study in 2001 by Li and
colleagues measured the antidepressant effects of the AMPA receptor potentiator LY392098 in
the rodent FST and TST. Acting similarly to a true agonist, a receptor potentiator increases
activity at receptor; however, a potentiator requires the presence and activation of the receptor by
the parent neurotransmitter, in this case glutamate. When both the neurotransmitter and a
receptor potentiator act at a receptor simultaneously, the potentiator increases the activity at the
receptor by keeping the ion channel open longer, allowing for greater excitement of the post24

synaptic neuron. Li and colleagues found that LY392098 attenuated behavioral despair (i.e.
possess antidepressant effects) in both models. Furthermore, pre-treatment with an AMPA
receptor antagonist, LY300168, blocked the antidepressant effects of LY392098 (Li et al., 2001).
In 2008, Maeng and colleagues investigated the relationship between NMDA and AMPA
receptors and demonstrated that AMPA receptor activation is required for ketamine’s
antidepressant effect. In this study, the researchers first administered the AMPA receptor
antagonist NBQX prior to the administration of ketamine to rodents prior to exposure to the FST
and found that pre-treatment with NBQX prevented ketamine’s antidepressant effects (Maeng et
al., 2008). These findings suggest that activation of the glutamatergic AMPA receptor is the true
mechanism that provides antidepressant effects.
Research from Li and colleagues proposes the exact pathway and methodology of how
AMPA receptor activation leads to an antidepressant response. Since it is well accepted that
AMPA receptor activation leads to the promotion of growth factors seen in LTP processes, the
study examined one of the intracellular protein kinases responsible for the cytoskeletal
reorganization and branching required in neurogenic processes, the mammalian target of
rapamycin (mTOR). The researchers hypothesized that since ketamine exerts its antidepressant
effects through AMPA receptor activation leading to LTP processes of synaptogenesis and
neurogenesis, that a pharmacological inhibition or blockade of the mTOR protein might prevent
ketamine’s antidepressant effects. In a drug challenge study, Li and colleagues inhibited the
mTOR pathway with the protein antagonist rapamycin prior to the administration of ketamine in
animals tested in the FST. The pre-treatment with rapamycin prevented ketamine from
demonstrating antidepressant effects in the model (Li et al., 2010). While inhibition of the
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mTOR pathway via rapamycin does provide us with an understanding of how ketamine might
indirectly provide its antidepressant effects, it does not answer the question of how ketamine, an
NMDA receptor antagonist, would potentiate or activate the nearby AMPA receptor.
More recent research performed in collaboration from various institutes including the
National Institute of Mental Health (NIMH) has provided a possible answer to this question.
There are numerous metabolites produced from the enzymatic breakdown of ketamine, and prior
research has demonstrated that only ketamine and its metabolite (R,S) norketamine produce
anesthesia, although (R,S) norketamine is less potent. Other ketamine metabolites fail to
produce any level of anesthesia, and as such, were thought to be biologically inactive. In an
extensive 2016 study, Zanos and colleagues examined the mechanisms behind ketamine’s
antidepressant effects, and included all of ketamine’s metabolites. First, they evaluated the
antidepressant effects of the NMDA antagonist ketamine compared to the tricyclic antidepressant
desimipramine at time points of 1-hour post drug administration and again at 24 hours post drug
administration. The researchers found that both desimipramine and ketamine demonstrated
antidepressant effects at the 1 hour mark, but only ketamine exhibited antidepressant effects at
the 24 hour mark. These findings are consistent with other preclinical findings and with the
clinical effects of ketamine’s anti-depressant effects. Furthermore, the researchers demonstrated
that the NMDA antagonist MK-801 produced antidepressant effects at the 1 hour mark, but
failed to produce antidepressant effects at the 24 hour mark in the FST. These findings led the
researchers to hypothesize that NMDA receptor antagonism may not be the mechanism behind
ketamine’s antidepressant effects. The researchers then evaluated the antidepressant effects of a
number of ketamine’s metabolites. Through evaluation in the FST, the researchers showed that
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similar to ketamine, a single administration of one ketamine metabolite, (2R,6R)hydronorketamine (HNK), induced persistent antidepressant effects lasting for at least 3 days of
testing in the FST. However, unlike ketamine, HNK did not displace MK-801 at the NMDA
receptor, suggesting that its mechanism of behavioral effects lies elsewhere. The researchers then
showed that HNK facilitates AMPA receptor activity via an increase in frequency and amplitude
of AMPA receptor excitatory potentials. Next the researchers sought to determine if AMPA
receptor activation is required in HNK’s antidepressant effects by performing a challenge study
wherein animals were pretreated with the AMPA antagonist NBQX prior to either ketamine or
HNK administration then evaluated in the FST. In line with research mentioned earlier,
pretreatment with NBQX prevented ketamine’s antidepressant effects. Furthermore, pretreatment with NBQX also prevented HNK’s antidepressant effects seen at both the 1 hour and
24 hour mark. As it has been implied that ketamine’s antidepressant effects are mediated through
both the activation of the mTOR protein and increased BDNF production, the researchers sought
to determine if HNK also increases activity or levels of these separate proteins. Interestingly, the
study showed that neither ketamine nor HNK produced increased activity in the mTOR protein
in hippocampal and prefrontal cortex tissue samples. However, both ketamine and HNK
increased hippocampal BDNF production. The researchers then demonstrated that both ketamine
and HNK produce increases in AMPA receptor expression 24 hours after administration.
Moreover, HNK’s antidepressant effects remained long after the time point where HNK was
undetectable in select brain tissue samples, suggesting its antidepressant effects are the result of
long-lasting synaptic changes as seen in LTP (Zanos et al., 2016).

27

2.6 Converging Lines of Evidence

A quick summary of the numerous lines of research discussed so far is necessary. Firstly,
separate research has demonstrated that traditional monoaminergic antidepressants induce the
production of the growth factor BDNF and that chronic administration of these compounds also
increases the expression of glutamatergic AMPA receptors and do so in a time-course that
resembles their antidepressant effects. Secondly, direct administration of BDNF has
demonstrated antidepressant effects in pre-clinical models of depression. Thirdly, numerous
clinical studies have detected glutamatergic alterations in MDD patients implying a role for
glutamate in the etiopathology of MDD. Finally, pharmacological potentiation of the
glutamatergic AMPA receptor has demonstrated antidepressant effects in pre-clinical models of
depression and pharmacological antagonism of the glutamatergic NMDA receptor via ketamine
has demonstrated antidepressant effects in both pre-clinical models and in a number of clinical
trials for both MDD, TRD, and bi-polar patients. Furthermore, pre-clinical studies have
demonstrated that AMPA receptor activation is required for ketamine’s antidepressant effects.
Combining these lines of research, a conclusion can be drawn that explains exactly how
monoaminergic antidepressants and ketamine produce their therapeutic effects. Chronic
administration of traditional antidepressants that target the monoaminergic system result in
increased expression of more AMPA receptors far downstream in the glutamatergic system, and
by doing so, allow for greater glutamate-AMPA receptor activity which stimulates the
underlying processes seen in LTP, such as production of and release of growth factors, namely
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BDNF. A number of studies have indicated that decreased levels of BDNF are associated with
MDD and that BDNF levels increase following antidepressant pharmacotherapy. (Duman and
Monteggia, 2006; Martinowich et al., 2007). Synaptic BDNF acts on both pre- and post-synaptic
tyrosine receptor kinase B (Trk-B) receptors and stimulate the mTOR protein pathway
responsible for cytoskeletal growth of new dendritic branches and axon terminals
(synaptogenesis), eventually leading to the growth of new neurons (neurogenesis). The resulting
increase in neuronal plasticity offsets the losses caused by stress-induced release of hormones.
However, more evidence is needed before concluding that these neuroplastic changes are the
underlying mechanisms behind the antidepressant effects seen across multiple
pharmacotherapies.
As mentioned in the earlier sections of this paper, prior to the discovery of the
hydrazines, outside of psychotherapy, the primary treatment method for depression was electroconvulsive shock therapy. While its biological effects were not understood at the time, advances
in science have allowed for closer examinations. Numerous studies have examined the
relationship and effect of ECT and biological alterations, specifically, changes to BDNF
production. In a systematic review and meta-analysis of both pre-clinical and clinical studies
investigating the effect of ECT on BDNF, Polyakova and colleagues found that animal and
human studies report similar findings in regard to effects of ECT on BDNF; that is, that ECT
increases brain BDNF in both preclinical and clinical studies. Moreover, multiple treatments
with ECT, compared to a single ECT treatment, were associated with larger increases in BDNF
in both animals and humans. These findings suggest that a dose-response relationship exists
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between the schedule of ECT and BDNF increases (Polyakova M., et al., 2015) and that
neuroplastic process are responsible for the antidepressant effects of ECT.
Though ECT may be an effective treatment option, it is generally a method of last resort
in depressed patients who have failed to respond to both pharmacotherapies and psychotherapies.
There are a variety of psychotherapies that have been employed to treat MDD including (but not
limited to) interpersonal therapy (IPT) and cognitive-behavioral therapy (CBT). Recent studies
have investigated the effects of such psychotherapies on the activity, volumetric size, and rate of
metabolism in key brain structures associated with MDD. Neuroimaging of MDD patients
reveals a decrease in activity and metabolism of cells within the dorsolateral prefrontal cortex
(DLPFC), which is correlated with depressive symptom severity (Brody et al., 2001). The
DLPFC is involved in executive functions such as working memory, cognitive flexibility,
planning, reasoning, and behavioral inhibition. On a note of interest, the main neurotransmitters
involved in DLPFC functioning are glutamate, dopamine, norepinephrine, and acetylcholine,
with very little serotonin activity. This may explain why some MDD patients fail to show
symptom relief with typical antidepressants designed to increase serotonin activity. A review by
Frewen and colleagues in 2008 found within therapy responders that both IPT and CBT restored
normal functioning of the DLPFC as measured by both rates of activity and metabolism (Frewen
et al., 2008). Frewen and colleagues also reported that the increased activity in DLPFC remained
long after the conclusion of therapy, findings resembling the effects of electrical stimulation and
the discovery of LTP process in the hippocampus by Bliss and Lomo mentioned earlier.
Furthermore, cognitive therapy has been demonstrated to increase the volume of grey matter in
the DLPFC (Seminowicz et al., 2013). Similarly, a study by Straub and colleagues found
30

increases in hippocampal activity in MDD patients following CBT (Straub et al., 2015), and a
2013 study by Moustafa reported increases in volumetric size of the hippocampus following 12
weeks of CBT (Moustafa, 2013). Together, these findings suggest that the various forms of
psychotherapy increase activity and volume of key brain structures involved in MDD, although
BDNF levels have not been directly measured, the increases in these measures implies the role
neuroplastic processes play in the benefits of psychotherapy.
Individuals suffering from MDD have provided anecdotal evidence suggesting that
physical exercise can alleviate depressive symptoms. And indeed, in a meta-analysis of
numerous scientific studies investigating such a relationship, Craft and Perna reported that
response rates in antidepressant-naïve MDD patients who engaged in moderate to high physical
exercise is slightly higher (approximately 70%-80%) on overage than patients taking
antidepressant pharmacotherapies alone (Craft and Perna, 2004). Subsequent studies have
demonstrated that exercise leads to an increase in BDNF production, particularly in the
hippocampus (Cotman et al., 2007), and this increase promotes improvement in cognitive
functioning and MDD symptoms (Marais et al., 2009; Russo-Neustadt et al., 2000). Again, these
findings in the effects of exercise suggest that neuroplastic changes underlie the benefits of
exercise in treating depression.
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3.0: CONCLUSION: THE STRESS-NEUROGENIC THEORY OF DEPRESSION

The purpose of this paper was to examine the discovery of the monoamine theory of
depression, evaluate its validity, and compare alternative treatment modalities in hopes of
identifying common biological effects. While the monoamine theory remains the dominant
explanatory model of MDD, the issues with its discovery and the shortcomings of
monoaminergic antidepressants listed above bring into question its validity. The measureable
downstream effects of conventional antidepressants on increased BDNF and up-regulation of
AMPA receptors suggest the true mechanism of monoaminergic antidepressants may not be the
direct elevation of synaptic monoamine levels. In short, I suggest that the Monoamine Theory of
MDD is incomplete.
There is mounting evidence for an alternative explanatory model for the etiopathology of
MDD, the Stress-Neurogenic Theory. This theory posits that unpredictable stress induces the
production of stress hormones that lead to neuronal death in key brain structures, such as the
hippocampus and amygdala, and this cell loss is responsible for the onset of MDD
symptomology. Psychological stress activates the release of a stress hormone from the
hypothalamus called corticotrophin-releasing hormone (CRH), which stimulates the pituitary
gland to release corticotrophin that then stimulates the adrenal gland to release cortisol.
Evidence of CRH’s role in the pathology of MDD can be found in elevated levels of CRH in the
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cerebrospinal fluid of MDD patients (Nemeroff, Widerlov, Bissette, 1984) as well as postmortem studies that have found increased numbers of CRH releasing neurons in the limbic
system structures in MDD patients (Raadsheer, Hoogendijk, Stam, 1994). Excessive levels of
cortisol can cause decreased neurogenesis, neurotoxicity, and neuronal cell death. It is believed
that repeated exposure to psychosocial stressors leads to over stimulation of the HPA-axis
resulting in increased levels of glucocorticoids. This increase in stress hormones is responsible
for the decrease in brain structure volume seen in the post-mortem studies of MDD patients.
Furthermore, the Stress-Neurogenic theory suggests that MDD can be treated by stimulating
synaptogenesis and neurogenesis in these structures, thus offsetting the neuronal loss due to
repeated over-exposure to stress hormones.
Evidence in support of this theory can be seen in all of the various treatment forms that
have efficacy in treating MDD. Typical monoaminergic antidepressants, ketamine and other
glutamatergic agents, ECT, various forms of psychotherapy, and even exercise have all
demonstrated the ability to increase either neurotrophic growth factors, such as BDNF, or
structural volume in key brain regions affected by excess stress hormones. By identifying this
commonality among the various treatment modalities, it is this author’s hope that by targeting
the brain’s natural neurogenic pathways, newer and faster acting antidepressants can be
identified for use in treating this debilitating disorder.
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